Differences in clinical variables at baseline in patients with radiographic progression in clinically active/inactive joints
| Progression+clinically active N=159 | Progression+clinically inactive N=120 | p Value | |
|---|---|---|---|
| RF (U/L), mean (±SD) | 159±303 | 106±171 | 0.51 |
| RF % positive | 61.0% | 58.3% | 0.65 |
| Anti-CCP Ab., mean (±SD) | 177±210 | 175±189 | 0.48 |
| Anti-CCP Ab. % positive | 65.4% | 75.0% | 0.08 |
| CRP (mg/dL), mean (±SD) | 0.9±1.4 | 0.8±1.5 | 0.06 |
| ESR (mm/h), mean (±SD) | 25.3±19.3 | 26.6±22 | 0.86 |
| HAQ, mean (±SD) | 0.9±0.7 | 0.6±0.7 | 0.003 |
| PGA, mean (±SD) | 33.1±23.4 | 22.2±21.9 | <0.0001 |
| EGA, mean (±SD) | 15.7±15.1 | 8.5±10.9 | <0.0001 |
| VAS, mean (±SD) | 32.1±22.8 | 21.9±20.7 | <0.0001 |
| CDAI, mean (±SD) | 11.6±10.3 | 5.5±6.6 | <0.0001 |
| SDAI, mean (±SD) | 12.5±10.4 | 6.1±6.7 | <0.0001 |
| DAS 28, mean (±SD) | 3.7±1.3 | 2.9±1.1 | <0.0001 |
| SHS at baseline, mean (±SD) | 40.1±53.4 | 59.7±73.4 | 0.015 |
Anti-CCP Ab, anti-CCP antibodies; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28, disease activity score 28; EGA, evaluators global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; PGA, patient global assessment; RF, Rheumatoid Factor; SDAI, simplified disease activity index; SHS, van der Heijde-Sharp-Score; VAS, pain on a visual analogue scale.